Market closed
Cidara Therapeutics/$CDTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cidara Therapeutics
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Ticker
$CDTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
38
ISIN
US1717572069
Website
CDTX Metrics
BasicAdvanced
$213M
-
-$20.89
-
-
Price and volume
Market cap
$213M
52-week high
$28.42
52-week low
$10.14
Average daily volume
143K
Financial strength
Current ratio
3.869
Quick ratio
3.48
Long term debt to equity
0.872
Total debt to equity
1.887
Management effectiveness
Return on assets (TTM)
-55.20%
Return on equity (TTM)
-299.58%
Valuation
Price to revenue (TTM)
563.58
Price to book
1.67
Price to tangible book (TTM)
1.67
Price to free cash flow (TTM)
-0.887
Growth
Revenue change (TTM)
-98.33%
Earnings per share change (TTM)
160.44%
3-year revenue growth (CAGR)
-82.28%
3-year earnings per share growth (CAGR)
10.79%
What the Analysts think about CDTX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cidara Therapeutics stock.
CDTX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CDTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CDTX News
AllArticlesVideos
Cidara Therapeutics, Inc. (CDTX) Q1 2025 Earnings Call Transcript
Seeking Alpha·3 days ago
Cidara Therapeutics: Strong Buy On Imminent Data Readout For Lead Flu Candidate
Seeking Alpha·1 week ago
Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cidara Therapeutics stock?
Cidara Therapeutics (CDTX) has a market cap of $213M as of May 14, 2025.
What is the P/E ratio for Cidara Therapeutics stock?
The price to earnings (P/E) ratio for Cidara Therapeutics (CDTX) stock is 0 as of May 14, 2025.
Does Cidara Therapeutics stock pay dividends?
No, Cidara Therapeutics (CDTX) stock does not pay dividends to its shareholders as of May 14, 2025.
When is the next Cidara Therapeutics dividend payment date?
Cidara Therapeutics (CDTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Cidara Therapeutics?
Cidara Therapeutics (CDTX) does not currently have a Beta indicator.